Immunic, Inc. (IMUX)
Immunic sets stage for phase 3 MS data readout after $400M financing
Immunic Inc (NASDAQ:IMUX) said it is entering a pivotal period for its multiple sclerosis program after securing up to $400 million in new financing and advancing its lead drug into late-stage development, with key data expected by the end of 2026. The biotechnology company's oral candidate, vidofludimus calcium (IMU-838), is currently being evaluated in the twin phase 3 ENSURE-1 and ENSURE-2 trials in relapsing multiple sclerosis (RMS).
Immunic closes $200M private placement to fund late-stage MS trials
Immunic Inc (NASDAQ:IMUX) said on Tuesday it has closed a previously disclosed private placement financing, raising $200 million upfront with the potential to secure up to an additional $200 million. The New York-based biotechnology company issued just over 229 million pre-funded warrants at a price of $0.873 each, generating gross upfront proceeds of $200 million.
Immunic MS trial shows reduced brain lesions - ICYMI
Immunic Inc (NASDAQ:IMUX)'s chief medical officer Dr Andreas Muehler talked with Proactive about new data presented at the ACTRIMS Forum in San Diego, highlighting findings from the company's phase 2 CALIPER trial in progressive multiple sclerosis (MS). Proactive: Hello, you're watching Proactive.
Immunic to raise up to $400M to fund late-stage MS trials, commercial push
Immunic Inc (NASDAQ:IMUX) announced that it has priced an oversubscribed private placement expected to generate up to $400 million in gross proceeds as the biotechnology company works to transition toward commercialization of its multiple sclerosis pipeline. The financing includes $200 million in upfront proceeds through the issuance of 229,076,000 pre-funded warrants priced at $0.873 each, with the potential for an additional $200 million from accompanying warrants if exercised.
Immunic to present additional Phase 2 data on vidofludimus calcium in progressive MS
Immunic Inc (NASDAQ:IMUX) said it will present additional analyses from its Phase 2 CALLIPER trial of vidofludimus calcium (IMU-838) in patients with progressive multiple sclerosis (PMS) at the ACTRIMS Forum 2026, which is being held from February 5 to 7 in San Diego. Vidofludimus calcium is described by Immunic as a nuclear receptor-related 1 (Nurr1) activator and selective dihydroorotate dehydrogenase (DHODH) inhibitor.
Immunic targets MS market with Phase 3 data - ICYMI
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive about the company's major milestones in 2025 and key expectations for 2026. He highlighted the significance of the phase 2 CALLIPER study, which demonstrated a 31% reduction in confirmed disability worsening in patients with progressive multiple sclerosis (MS), and a 34% reduction in those without baseline gadolinium lesions.
Immunic looks to 2026 data as late-stage MS program advances
Immunic Inc (NASDAQ:IMUX) said on Wednesday it is entering a pivotal phase for its lead multiple sclerosis drug as the biotech company prepares for key clinical readouts that could shape its longer-term growth strategy. The Nasdaq-listed company said it has completed patient enrollment in two late-stage Phase 3 trials of vidofludimus calcium, an oral therapy being tested in relapsing multiple sclerosis (RMS), and expects synchronized top-line results by the end of 2026.
Immunic's long-term treatment hope for multiple sclerosis – ICYMI
Immunic Inc (NASDAQ:IMUX) earlier this week highlighted the long-term clinical potential of its lead compound vidofludimus calcium in treating multiple sclerosis (MS). Speaking to Proactive, Chief Scientific Officer Dr.
Immunic advances MS therapy vidofludimus calcium during Q3 - ICYMI
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive about the company's third quarter highlights, with a particular focus on the progress of its oral MS treatment, vidofludimus calcium. Dr Vitt noted the company had a strong presence at the 2025 ECTRIMS conference, presenting important new data from several clinical studies.
Immunic advances MS program with key clinical findings in Q3
Immunic Inc (NASDAQ:IMUX) highlighted positive clinical results for its lead drug candidate, vidofludimus calcium, showing statistically significant improvement in progressive multiple sclerosis (MS), as the company reported its third quarter 2025 financial results and provided a corporate update. At the 41st Congress of ECTRIMS in September, Immunic presented data from the Phase 2 CALLIPER trial, which showed a greater than two-fold probability of 24-week confirmed disability improvement versus placebo in patients with progressive multiple sclerosis (PMS).
Immunic targeting mental and physical challenges facing MS patients - ICYMI
Immunic Inc (NASDAQ:IMUX) Chief Scientific Officer Dr Hella Kohlhof talked with Proactive about the company's research focus on multiple sclerosis (MS), highlighting how Immunic is aiming to address both the physical and mental health challenges faced by patients. Kohlhof explained the strong link between MS and mental health conditions such as depression and anxiety, noting that studies show around 30% of patients experience depression, while 20% experience anxiety.
Immunic highlights multiple sclerosis drug findings at key neurology gathering
Immunic Inc (NASDAQ:IMUX) has presented clinical trial data suggesting its oral therapy, vidofludimus calcium, could help slow disability in patients with progressive multiple sclerosis, a form of the disease that remains difficult to treat. The results were shared at the annual congress of the European Committee for Treatment and Research in Multiple Sclerosis in Barcelona, one of the largest gatherings of neurologists and researchers in the field.
